Rofecoxib (Vioxx), a specific cyclooxygenase-2 inhibitor, is chemopreventive in a mouse model of colon cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 26, Issue 4 SUPPL. 2, 2003, Pages

  Evans, Jilly F ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ROFECOXIB; SULINDAC; TUMOR SUPPRESSOR PROTEIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER INHIBITION; CHEMOPROPHYLAXIS; COLON CANCER; CONFERENCE PAPER; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME ACTIVITY; HIGH RISK PATIENT; IC 50; INTESTINE POLYP; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; GENES, APC; ISOENZYMES; LACTONES; MICE; MICE, KNOCKOUT; MODELS, ANIMAL; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SULFONES; SULINDAC;

EID: 0043075955     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200308002-00005     Document Type: Conference Paper

References (20)

1. Marnett LJ. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992;52:5575-89.
2. Xie WL, Chipman JG, Robertson DL, et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci U S A 1991;88:2692-6.
3. Fletcher BS, Kujubu DA, Perrin DM, et al. Structure of the mitogen-inducible TIS10 gene and demonstration that the TIS10-encoded protein is a functional prostaglandin G/H synthase. J Biol Chem 1992;267:4338-44.
4. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci U S A 1992;89:7384-8.
5. Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-8.
6. Kargman S, O'Neill G, Vickers P, et al. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 1995;55:2556-9.
7. DuBois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J 1998;12:1063-73.
8. Oshima M, Oshima H, Kitagawa K, et al. Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene. Proc Natl Acad Sci U S A 1995;92:4482-6.
9. Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803-9.
10. Δ716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 2001;61:1733-40.
11. Beazer-Barclay Y, Ley DB, Moser AR, et al. Sulindac suppresses tumorigenesis in the Min mouse. Carcinogenesis (Lond) 1996;17:1757-60.
12. Giardello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-6.
13. Lal G, Ash C, Hay K, et al. Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor. Cancer Res 2001;61:6131-6.
14. Cannon GW, Caldwell JR, Holt P, et al. Rofecoxib, a specific inhibitor of cyclooxygenase-2, with clinical efficacy comparable with that of diclofenac sodium. Arthritis Rheum 2000;43:978-87.
15. Porras A, Ko A, Larson P, et al. Single and multiple dose pharmacokinetics (PK) of rofecoxib (R) in healthy subjects [Abstract PII]. Am Soc Clin Pharm Ther 2000;67:137.
16. Brideau C, Kargman S, Liu S, et al. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm Res 1996;45:68-74.
17. Kanfer I, Brown C, Konings M, Swarbrick J. Absorption of sulindac from a novel (Pro-Sorb™) liquid formulation. Biopharm Drug Dispos 1996;17:209-21.
18. Sonoshita M, Takaku K, Sasaki N, et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in knockout mice. Nature Med 2001;7:1048-51.
19. Williams CS, Tsujii M, Reese J, et al. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000;105:1589-94.
20. Stolina M, Sharma S, Lin Y, et al. Specific inhibition of cyclooxygenase-2 restores anti-tumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 2000;164:361-70.